RNA Interference Markets - Biotechnology, Healthcare and Life Sciences Publishing

Home > Browse Reports > Biotechnology > RNA Interference Markets

Report Description

RNA Interference Markets
Publication Date: 01-MAY-08
Pages: 122
Study: TMRRNAI
Format/Price: PDF document / $1,999.00

Description:

View Sample PDF

Since its discovery, the naturally occurring RNA (ribonucleic acid) interference effect has been acclaimed as the most exciting technical breakthrough in biological research in the last decade. Some industry analysts predict that RNA interference (RNAi) may even surpass PCR as a top technology. RNAi allows scientists to silence the expression or effect of a gene under study. This is known as gene knockdown. This field has rapidly emerged as a fast-growing new market. The purpose of this TriMark Publications report is to review the market for RNAi testing equipment and supplies. RNAi is a mechanism in molecular biology where the presence of certain fragments of double-stranded RNA (dsRNA) interferes with the expression of a particular gene which shares a similar sequence with the dsRNA. This study defines the dollar volume of sales, both worldwide and in the U.S., and analyzes the factors that influence market size and growth for RNAi testing. The main objectives of this study are to: 1) understand the different sectors of RNAi testing market and to look at a description of the instruments, reagents and supplies marketed by major companies in each segment; 2) obtain a complete understanding of the individual RNAi-testing platforms-from basic principles to clinical applications; 3) discover feasible market opportunities by identifying high-growth applications in different analytical diagnostic areas, with a focus on the biggest and expanding markets; 4) focus on global industry developments and trends through an in-depth analysis of the major world markets for RNAi measurement technology, including growth forecasts; and 5) present market figures related to the current value of RNAi testing, market projections, market share, key players and sector growth rates.

Table of Contents:

1. Overview 5
1.1 Objectives 5
1.2 Scope 5
1.3 Methodology 7
1.4 Executive Summary 8
2. RNA Interference (RNAi) 11
2.1 Introduction 11
2.2 Overview of RNA Interference 11
2.2.1 Classes of Endogenous Small RNAs: siRNA, rasiRNA and miRNA 12
2.2.2 Mechanism of RNAi In Vivo 13
2.3 Glossary 16
2.4 What Areas of Research Does RNAi Impact? 17
2.4.1 RNAi Technology in Life Sciences Research, Drug Discovery and Development 18
2.4.1.1 Clinical Trials Featuring RNAi-based Therapeutics 20
2.4.2 RNAi Technology in Agriculture 24
2.4.2.1 Companies Utilizing RNAi Technology for Agriculture 25
3. Technology Trends in RNAi Space 27
3.1 Overview 27
3.2 End-User Segmentation 27
3.3 Technologies for Inducing RNAi 28
3.3.1 Methods for Detecting Gene Silencing 29
3.3.2 Libraries of siRNAs/shRNAs to Knockdown Genes En Masse 30
3.3.2.1 Publicly Available Large-scale Mammalian RNAi Libraries 31
3.3.2.2 The RNAi Consortium (TRC) 32
3.3.2.3 RNAi-related Consortia Based in Europe 34
3.3.3 Comparison of Strategies for Target Validation 36
3.3.3.1 Market Shifts in RNAi Space: Where Is It Headed? 36
3.3.3.2 Intellectual Property and Patent Issues 37
3.3.3.3 Funding in RNAi Space: Grants, Venture Capital and IPOs 39
3.3.3.4 Partnerships, Alliances, Mergers and Acquisitions 41
3.3.4 miRNA-Based RNAi: Leading Edge of RNAi Space 43
3.3.4.1 Biological Function of miRNAs 43
3.3.4.2 Role of miRNAs in Disease 44
4. RNAi Market Analysis 54
4.1 Overview 54
4.2 Market Data Collection and Respondent Pool 54
4.2.1 Respondent Pool Characteristics 55
4.3 RNAi Technologies/Products in Research Applications 57
4.4 RNAi Technologies/Products: Market Shares (Quantitative) 57
4.5 Quantitative Metrics of RNAi Usage: Market Opportunity and Growth 60
4.5.1 Growth of Various Segments in RNAi Space 62
4.5.2 Product Formats and Representation in RNAi Marketplace 63
4.6 RNAi Marketplace: Challenges, Unmet Needs and Drivers 69
4.6.1 Unmet Needs in RNAi Space 70
4.6.2 RNAi Market: Qualitative Growth Drivers 72
5. The RNAi Landscape 73
5.1 Overview 73
5.2 Market Segmentation of RNAi and Segment Characteristics 73
5.3 Quantitative Market Opportunities in RNAi Space 75
5.3.1 Opportunities in miRNA Space 75
5.3.2 Opportunities in siRNA/shRNA Space 77
5.4 RNAi Product Offerings and Associated Business Models 78
6. Company Profiles 81
6.1 Alfacell Corporation 82
6.2 Allele Biotechnology and Pharmaceuticals, Inc. 82
6.3 Alnylam Pharmaceuticals 82
6.4 Ambion 84
6.5 Applied Biosystems Group 84
6.6 Asuragen, Inc. 85
6.7 Avalon Pharmaceuticals, Inc. 85
6.8 B-Bridge International, Inc. 85
6.9 Bio-Rad Laboratories 86
6.10 Calando Pharmaceuticals, Inc. 86
6.11 Cepheid 87
6.12 Cequent 87
6.13 Clontech Laboratories, Inc. 87
6.14 CombiMatrix Corporation 88
6.15 Cyntellect, Inc. 88
6.16 CytRx Corp. 88
6.17 Dharmacon 89
6.18 Dicerna 90
6.19 Galenea Corporation 90
6.20 GeneCopoeia, Inc. 90
6.21 GeneThera, Inc. 91
6.22 Genlantis 91
6.23 GenoSensor 91
6.24 GRL, Inc. 91
6.25 IDT 92
6.26 Imgenex Corporation 92
6.27 Ingenuity Systems 92
6.28 Isis Pharmaceuticals, LLC 92
6.29 Intradigm Corporation 94
6.30 Invitrogen 94
6.31 InvivoGen 95
6.32 LC Sciences 95
6.33 Lentigen Corporation 95
6.34 Merck & Co., Inc. 95
6.35 Mirus Bio Corporation 96
6.36 Monsanto 96
6.37 Nastech Pharmaceutical Company, Inc. 96
6.38 New England BioLabs 97
6.39 Nucleonics, Inc. 97
6.40 Open Biosystems, Inc. 97
6.41 OPKO Health, Inc. 98
6.42 OriGene 98
6.43 Panomics, Inc. 99
6.44 PhaseRx 99
6.45 Promega Corp. 99
6.46 Quark Pharmaceuticals, Inc. 99
6.47 RXi Pharmaceuticals Corporation 100
6.48 Senetek PLC 100
6.49 Sigma-Aldrich 100
6.50 Sirna Therapeutics 101
6.51 Sirnaomics, Inc. 101
6.52 SomaGenics, Inc. 102
6.53 System Biosciences 103
6.54 Tacere Therapeutics 103
6.55 Targeted Genetics Corporation 104
6.56 Third Wave Technologies 104
6.57 Traversa 104
6.58 Actigenics SA 105
6.59 Amaxa 105
6.60 AstraZeneca PLC 106
6.61 Cenix Bioscience GmbH 106
6.62 deVGen N.V. 107
6.63 DNAVision 107
6.64 Exiqon 107
6.65 Genovis 108
6.66 genOway 108
6.67 imaGenes GmbH 108
6.68 MWG Biotech AG 109
6.69 OZ Biosciences 109
6.70 Prosensa Holding 109
6.71 QIAGEN 110
6.72 RNAx GmbH (Germany) 111
6.73 Roche 112
6.74 Rosetta Genomics, Ltd. 113
6.75 Santaris Pharma A/S 113
6.76 Silence Therapeutics PLC 114
6.77 TaconicArtemis GmbH 114
6.78 TRANSAT 114
6.79 alphaGEN Co., Ltd. 115
6.80 Benitec, Ltd. 116
6.81 Bioneer 116
6.82 CytoPathfinder, Inc. 116
6.83 Genesis Research & Development Corp. 117
6.84 GeneDesign, Inc. 117
6.85 GNI Pharmaceutical Corporation 117
6.86 Koken Co., Ltd. 118
6.87 NanoCarrier Co., Ltd. 118
6.88 Oncolys Biopharma, Inc. 118
6.89 RealGene Bio-Technologies, Inc. 118
6.90 Samchully Pharmaceuticals 118
6.91 Samyang Corp. 119
6.92 Shanghai Biochip 119
6.93 Shanghai GenePharma Co. 119
6.94 Shanghai Genomics, Inc. 120
6.95 Transgene Biotek, Ltd. 120
6.96 Tekmira 121
INDEX OF TABLES
Table 2.1: Advantages/Disadvantages of siRNAs and shRNAs as Inducers of RNAi in Mammalian Cells 18
Table 2.2: Prevalence of siRNA-mediated RNAi in Disease Models, as Reported in Scientific Literature 20
Table 2.3: RNAi-based Therapeutics in Clinical Trials 21
Table 2.4: Suppliers of Enabling Technologies and Tools in RNAi Space 22
Table 2.5: Suppliers of siRNA/shRNA Products (by Product/Service Class) 23
Table 3.1: Currently Utilized Technologies for Inducing RNAi-Mediated Knockdown 29
Table 3.2: Comparison of mRNA Detection Technologies 29
Table 3.3: Characteristics of Various Publicly available Mouse and Human RNAi Libraries 31
Table 3.4: Comparison of Formats for Library-Based Gene Knockdown 33
Table 3.5: Strategies for Target Validation by Pharma/Biotech: RNAi and Others 36
Table 3.6: Seminal Patents in RNAi 39
Table 3.7: Venture Capital Raised by Selected Companies in the RNAi Space 40
Table 3.8: List of Public Biotech Companies in RNAi Space 41
Table 3.9: Disease-Related miRNAs 48
Table 3.10: Publicly Available Computational Programs for Identifying miRNA Sequences/Targets 49
Table 3.11: SWOT Analysis of siRNA Oligonucleotides 52
Table 3.12: Transfection Reagents (Lipid-Mediated Delivery) 52
Table 3.13: shRNA Plasmid Constructs 53
Table 3.14: shRNA Pooled Libraries or Arrayed Collections (Retroviral/Lentiviral Delivery) 53
Table 5.1: RNAi Market Segmentation and Research Settings 73
Table 5.2: Segment 1: Basic Life Science Research Utilizing RNAi Tools and Technologies 73
Table 5.3: Segment 2: RNAi for Drug Discovery and Development 74
Table 5.4: Segment 3: RNAi Research for Development of RNAi Therapeutics 74
Table 5.5: Segment 4: RNAi Fee-for-Service Business 75
Table 5.6: Grants Awarded and Research Spending in miRNA Space, 2005-2008 75
Table 5.7: RNAi Opportunity and Market Size: Quantitative Model, 2006-2009 77
INDEX OF FIGURES
Figure 2.1: The miRNA Processing Pathway 14
Figure 2.2: Growth of Scientific Publications Addressing miRNAs, 2001-2008 15
Figure 2.3: Mechanisms of Small RNA-induced Gene Regulation 16
Figure 2.4: Types of RNAi Compounds 18
Figure 2.5: Breakdown of Scientific Publications Related to RNAi by Geographic Region, 2007-2008 19
Figure 3.1: End-User Segmentation of RNAi Space 27
Figure 3.2: RNAi Patents Filed Globally, by Geographical Origin 39
Figure 3.3: Selected Deals in RNAi Space 42
Figure 4.1: Geographical Breakdown of RNAi End-User Survey Respondents 55
Figure 4.2: Affiliation of RNAi End-User Survey Respondents 55
Figure 4.3: Utilization of RNAi Technologies/Products by Respondent Pool 56
Figure 4.4: RNAi Utilization Period: Breakdown of Respondent Pool 56
Figure 4.5: Research Applications Using RNAi Technologies/Products 57
Figure 4.6: Types of RNAi Technologies Currently Utilized 58
Figure 4.7: RNAi Technologies Most Commonly Utilized Currently by End-Users 58
Figure 4.8: Types of RNAi Technologies: Expected Use in Six to 18 Months 59
Figure 4.9: Evolution of Market Shares of RNAi-Inducing Technologies 60
Figure 4.10: Number of Experiments Involving RNAi Conducted per Week 60
Figure 4.11: Range of Research Dollars Spent Monthly on RNAi Research 61
Figure 4.12: RNAi Experiment Throughput Correlated with Type of RNAi Technology Used 62
Figure 4.13: Current RNAi Market Share by Segments 63
Figure 4.14: Growth/Decline Rate of RNAi Marketplace Segments (Six to 18 Months) 64
Figure 4.15: Product Formats Utilization for RNAi Research (Current and Six to 18 Months) 65
Figure 4.16: Companies Offering Product Formats for Currently Used RNAi Products 67
Figure 4.17: RNAi Product Offerings/Formats Use (Projections-Six to 18 Months) 68
Figure 4.18: Percentage Change of RNAi Product Offerings/Formats (Six to 18 Months) 69
Figure 4.19: Key Challenges Faced by End-Users in RNAi Space 70
Figure 4.20: Unmet Needs in RNAi Space Ranked by Importance to End-Users 71
Figure 5.1: Growth and Evolution of miRNA Space 76
Figure 5.2: Elements of RNAi Value Chain 77
Figure 5.3: Growth and Evolution of RNAi (siRNA/shRNA) Space 78
Figure 5.4: Market Revenues Based on Components of siRNA Experimental Paradigm 80

Home | Reports | Database Tables | Conferences | Contact Us